Evidence map›Paper›PMID 42905724›Full record

ArticlePloS one2026

Blood biomarkers of long COVID: A cross-sectional evaluation of key cytokines and the coordination of inflammation.

Callum Thomas, Ruth E Ashton, Etheresia Pretorius, Rebecca Owen, Massimo Nunes, Jan H Pretorius, Isaac T Shawa, Corinna Chidley, Mark A Faghy

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Callum ThomasSchool of Health, Sport and Rehabilitation, College of Health and Humanities, University of Derby, Derby, United Kingdom.ORCID https://orcid.org/0000-0001-8608-8231
Ruth E AshtonResearch Centre for Healthcare and Communities Transformation, Coventry University, Coventry, United Kingdom.ORCID https://orcid.org/0000-0001-6282-0352
Etheresia PretoriusDepartment of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa.ORCID https://orcid.org/0000-0002-9108-2384
Rebecca OwenSchool of Health, Sport and Rehabilitation, College of Health and Humanities, University of Derby, Derby, United Kingdom.
Massimo NunesDepartment of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, South Africa.
Jan H PretoriusDepartment of Economics, Faculty of Economic and Management Sciences, Stellenbosch University, Stellenbosch, South Africa.
Isaac T ShawaSchool of Health, Sport and Rehabilitation, College of Health and Humanities, University of Derby, Derby, United Kingdom.
Corinna ChidleySchool of Health, Sport and Rehabilitation, College of Health and Humanities, University of Derby, Derby, United Kingdom.
Mark A FaghySchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, United Kingdom.ORCID https://orcid.org/0000-0002-8163-7032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLong COVID is a complex pathophysiological condition linked to a heterogenous symptom profile. Dysregulation of 1) immunological and inflammatory responses, 2) endothelial/vascular function, and 3) metabolic and clotting processes have been identified; however, there remains a lack of clinically validated diagnostic biomarkers. The study aim was to investigate dysregulation of cytokines, chemokines and growth factors in confirmed Long COVID cases grouped by disease severity.

methodsOne-hundred-and-twenty-seven participants provided venous blood samples for cytokine profiling utilising Luminex assays. Participants were grouped into those with no knowledge of SARS-CoV-2 infection (n = 21), acute infection within 3-months (n = 22), spontaneous resolvers (>3-months, n = 21) and those with confirmed Long COVID (n = 63). Long COVID severity was grouped according to the post-COVID-19 functional status (PCFS) and defined as those with negligible (4A; n = 9), mild (4B; n = 20), moderate (4C; n = 24), and severe limitations (4D; n = 10). Cytokines were assessed for normality using Shapiro-Wilk tests and differences measured between groups using Kruskal-Wallis tests. Pairwise correlation and principal component analysis were performed.

resultsInterleukin-12 (p40/p70) was 22% greater in the Long COVID group (Median [IQR]: 58 [49] pg/mL, p = 0.046) and 30% greater in the acutely infected group (64 [36] pg/mL; p = 0.039) against non-infected controls (45 [25] pg/mL). Following PCFS classification, fibroblast growth factor-basic was 25% lower in Long COVID 4B versus spontaneous resolvers (24 [7] vs. 32 [24] pg/mL; p = 0.025). Pairwise correlation differences demonstrated that three Long COVID subgroups had strong, positive associations between cytokines when compared to non-infected controls; however, PCA was unable to determine any coordinated cytokine variation that was group specific. DISCUSSION AND

conclusionsElevated interleukin-12 (p40/p70) and reduced basic fibroblast growth factor suggest persistent immune activation and possible subgroup-specific Long COVID; however, these findings were marginally significant and exploratory. A coordinated but partial immunological/inflammatory profile may exist in some of those with Long COVID, suggesting a rationale for subgrouping upon a biological, rather than self-report basis but larger longitudinal studies are required to confirm this hypothesis.

Indexed as

Coronavirus InfectionsCOVID-19CytokinesInflammationAdultAgedBiomarkersChemokinesCross-Sectional StudiesFemaleHumansMaleMiddle AgedPost-Acute COVID-19 SyndromeSARS-CoV-2Severity of Illness IndexBiomarkersChemokinesCytokines

Identifiers

PMID42905724
PMCPMC13686509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.